{"product_id":"american-society-of-clinical-oncology-genitourinary-cancers-symposium-2025","title":"American Society of Clinical Oncology Genitourinary Cancers Symposium 2025","description":"\u003cul\u003e\n  \u003cli\u003eInclude:  videos +  pdf, size:  GB\u003c\/li\u003e\n  \u003cli\u003eTarget Audience: oncologists, urologists, radiation oncologists\u003c\/li\u003e\n  \u003cli\u003eSample video: contact me for sample video\u003c\/li\u003e\n  \u003cli\u003eInformation:\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThe American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium 2025 is a premier event focused on the latest advancements in prostate, bladder, kidney, and other genitourinary cancers. It brings together oncologists, researchers, and healthcare professionals to discuss cutting-edge treatments, clinical trials, and emerging therapies.\u003c\/p\u003e\n\u003ch3\u003eHere are some key details:\u003c\/h3\u003e\n\u003cp\u003eLocation: San Francisco, CA\u003c\/p\u003e\n\u003ch3\u003eProgram Highlights:\u003c\/h3\u003e\n\u003cp\u003eProstate Cancer: Advances in radioligand therapies and androgen receptor pathway inhibitors.\u003c\/p\u003e\n\u003cp\u003eBladder Cancer: Innovations in antibody drug conjugates and immunotherapy.\u003c\/p\u003e\n\u003cp\u003eKidney Cancer: Biomarkers and new treatment strategies.\u003c\/p\u003e\n\u003cp\u003eUpper Tract Urothelial Carcinoma: Kidney-sparing approaches and perioperative therapies.\u003c\/p\u003e\n\u003ch3\u003eThe American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium 2025 is tailored for professionals involved in genitourinary oncology, including:\u003c\/h3\u003e\n\u003cp\u003eMedical oncologists specializing in prostate, bladder, kidney, and other genitourinary cancers.\u003c\/p\u003e\n\u003cp\u003eUrologists and radiation oncologists focused on multimodal treatment strategies.\u003c\/p\u003e\n\u003cp\u003eResearchers and scientists presenting groundbreaking studies on biomarkers and emerging therapies.\u003c\/p\u003e\n\u003cp\u003eHealthcare providers interested in the latest advancements in immunotherapy, targeted treatments, and surgical innovations.\u003c\/p\u003e\n\u003cp\u003ePharmaceutical and biotech professionals exploring novel drug developments.\u003c\/p\u003e\n\u003cp\u003ePatient advocates and policy experts working to improve cancer care accessibility.\u003c\/p\u003e\n\u003cp\u003eThe symposium offers multidisciplinary perspectives, interactive sessions, and networking opportunities to enhance patient outcomes.\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eTopics:\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThursday, February 13, 2025\u003c\/p\u003e\n\u003cp\u003e7:00 AM-\u003c\/p\u003e\n\u003cp\u003e8:00 AM\u003c\/p\u003e\n\u003cp\u003eComplimentary Continental Breakfast\u003c\/p\u003e\n\u003cp\u003e7:00 AM-\u003c\/p\u003e\n\u003cp\u003e6:45 AM\u003c\/p\u003e\n\u003cp\u003eExhibits Open\u003c\/p\u003e\n\u003cp\u003e8:00 AM-\u003c\/p\u003e\n\u003cp\u003e9:40 AM\u003c\/p\u003e\n\u003cp\u003eOral Abstract Session A: Prostate CancerKosj Yamoah, MD, PhD—Chair\u003c\/p\u003e\n\u003cp\u003eH. Lee Moffitt Cancer Center and Research InstituteChanning Judith Paller, MD—Chair\u003c\/p\u003e\n\u003cp\u003eThe Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsPeter Hoskin, MD, FRCP, FRCR\u003c\/p\u003e\n\u003cp\u003eWelcome of the Day\u003c\/p\u003e\n\u003cp\u003eABSTRACT 308: Gene signature predictor of dose-response to prostate radiation: Validation of PORTOS in phase III trials.\u003c\/p\u003e\n\u003cp\u003eABSTRACT 309: Radical prostatectomy (RP) versus radiotherapy (RT) in high-risk prostate cancer (HR-PCa): Emulated randomized comparison with individual patient data (IPD) from two phase III randomized trials (RCTs).\u003c\/p\u003e\n\u003cp\u003eEdwin Posadas, MD, FACP\u003c\/p\u003e\n\u003cp\u003eCedars-Sinai Medical Center\u003c\/p\u003e\n\u003cp\u003eDiscussion\u003c\/p\u003e\n\u003cp\u003eABSTRACT 20: Which patients with metastatic hormone-sensitive prostate cancer (mHSPC) benefit more from androgen receptor pathway inhibitors (ARPIs)? STOPCAP meta-analyses of individual participant data (IPD).\u003c\/p\u003e\n\u003cp\u003eTanya B. Dorff, MD\u003c\/p\u003e\n\u003cp\u003eCity of Hope Comprehensive Cancer Center\u003c\/p\u003e\n\u003cp\u003eDiscussion\u003c\/p\u003e\n\u003cp\u003ePanel Question and Answer\u003c\/p\u003e\n\u003cp\u003eBreak\u003c\/p\u003e\n\u003cp\u003eUnderstanding Radioligand Therapies for Advanced Prostate CancerAngela Y Jia, MD, PhD—Chair\u003c\/p\u003e\n\u003cp\u003eUniversity Hospitals Seidman Cancer Center and Case Western Reserve UniversityDevaki Shilpa Surasi, MBBS—Chair\u003c\/p\u003e\n\u003cp\u003eUniversity of Texas at MD Anderson Cancer Center\u003c\/p\u003e\n\u003cp\u003ePSMA-Based Therapy in Advanced Disease: Touching on Combination SequencingWilliam Kevin Kelly, DO\u003c\/p\u003e\n\u003cp\u003eThomas Jefferson University Hospital\u003c\/p\u003e\n\u003cp\u003eBeyond PSMA-Targeted Agents for Advanced Disease\u003c\/p\u003e\n\u003cp\u003eDanny Mena Cortes\u003c\/p\u003e\n\u003cp\u003eNuclear Medicine World\u003c\/p\u003e\n\u003cp\u003eSeeing Is Believing: Radiographic Criteria to Assess Response\u003c\/p\u003e\n\u003cp\u003ePanel Question and Answer\u003c\/p\u003e\n\u003cp\u003ePoster Session A: Prostate Cancer\u003c\/p\u003e\n\u003cp\u003eWith Complimentary Boxed Lunch\u003c\/p\u003e\n\u003cp\u003eTrials in Progress Poster Session A: Prostate Cancer\u003c\/p\u003e\n\u003cp\u003eWith Complimentary Boxed Lunch\u003c\/p\u003e\n\u003cp\u003eTrainee and Early-Career Networking LuncheonView the networking faculty list here\u003c\/p\u003e\n\u003cp\u003eCase-Based Session: Management of Biochemical Recurrence After Radiation Therapy for Localized Prostate CancerMichael Cookson, MD, MMHC, FACS—Chair\u003c\/p\u003e\n\u003cp\u003eUniversity of Oklahoma College of MedicineBarbara Jereczek-Fossa, MD—Chair\u003c\/p\u003e\n\u003cp\u003eIEO European Institute of Oncology IRCCSMichael Cookson, MD, MMHC, FACS\u003c\/p\u003e\n\u003cp\u003eUniversity of Oklahoma College of Medicine\u003c\/p\u003e\n\u003cp\u003eRecurrence After Radiation Therapy: Evaluation, Management, and Outcomes\u003c\/p\u003e\n\u003cp\u003eHeather H. Cheng, MD, PhD\u003c\/p\u003e\n\u003cp\u003eUniversity of Washington\u003c\/p\u003e\n\u003cp\u003eMedical Oncology\u003c\/p\u003e\n\u003cp\u003eJuanita Crook, FRCPC\u003c\/p\u003e\n\u003cp\u003eThe University of British Columbia\u003c\/p\u003e\n\u003cp\u003eRadiation Oncology\u003c\/p\u003e\n\u003cp\u003eThomas Polascik, MD\u003c\/p\u003e\n\u003cp\u003eDuke University Division of Urologic Surgery\u003c\/p\u003e\n\u003cp\u003eUrology (Ablative Focal)\u003c\/p\u003e\n\u003cp\u003eAshley Ross, MD, PhD\u003c\/p\u003e\n\u003cp\u003eNorthwestern University Feinberg School of Medicine\u003c\/p\u003e\n\u003cp\u003eUrology (Salvage Surgery)\u003c\/p\u003e\n\u003cp\u003eAlicia K. Morgans, MD, MPH, FASCO\u003c\/p\u003e\n\u003cp\u003eDana-Farber Cancer Institute\u003c\/p\u003e\n\u003cp\u003eThe Impact of Salvage Therapies: Functional Outcomes and Quality of Life\u003c\/p\u003e\n\u003cp\u003ePanel Question and Answer\u003c\/p\u003e\n\u003cp\u003eKeynotePeter Hoskin, MD, FRCP, FRCR – Chair\u003c\/p\u003e\n\u003cp\u003eMount Vernon Cancer Centre, University College London, and University of Manchester\u003c\/p\u003e\n\u003cp\u003eIntroduction of Dr. DahutWilliam L. Dahut, MD\u003c\/p\u003e\n\u003cp\u003eAmerican Cancer Society\u003c\/p\u003e\n\u003cp\u003eCreative Innovation: Driving Science to Improve Patient-Centered CareQuestion and Answer\u003c\/p\u003e\n\u003cp\u003e3:05 PM-\u003c\/p\u003e\n\u003cp\u003e3:30 PM\u003c\/p\u003e\n\u003cp\u003eBreak\u003c\/p\u003e\n\u003cp\u003e3:30 PM-\u003c\/p\u003e\n\u003cp\u003e4:45 PM\u003c\/p\u003e\n\u003cp\u003eCase-Based Session: Evolving Landscape of the Management of Oligometastatic DiseaseKaren E. Hoffman, MD, MHSc, MPH—Chair\u003c\/p\u003e\n\u003cp\u003eThe University of Texas MD Anderson Cancer CenterNicholas David James—Chair\u003c\/p\u003e\n\u003cp\u003eInstitute of Cancer Research, The Royal Marsden Hospital NHS Foundation TrustABSTRACT 15: World-wide oligometastatic prostate cancer (omPC) meta-analysis leveraging individual patient data (IPD) from randomized trials (WOLVERINE): An analysis from the X-MET collaboration.\u003c\/p\u003e\n\u003cp\u003eKenneth L. Gage, MD, PhD\u003c\/p\u003e\n\u003cp\u003eH. Lee Moffitt Cancer Center and Research Institute\u003c\/p\u003e\n\u003cp\u003eRadiology\u003c\/p\u003e\n\u003cp\u003eBrandon A. Mahal, MD\u003c\/p\u003e\n\u003cp\u003eUniversity of Miami\u003c\/p\u003e\n\u003cp\u003eRadiation Oncology\u003c\/p\u003e\n\u003cp\u003eKasmintan A. Schrader, PhD, MBBS\u003c\/p\u003e\n\u003cp\u003eBC Cancer\u003c\/p\u003e\n\u003cp\u003eGenetics\u003c\/p\u003e\n\u003cp\u003eSandy Srinivas, MD\u003c\/p\u003e\n\u003cp\u003eStanford School of Medicine\u003c\/p\u003e\n\u003cp\u003eMedical Oncology\u003c\/p\u003e\n\u003cp\u003ePanel Question and Answer\u003c\/p\u003e\n\u003cp\u003e5:00 PM-\u003c\/p\u003e\n\u003cp\u003e5:45 PM\u003c\/p\u003e\n\u003cp\u003eRapid Oral Abstract Session A: Prostate CancerMarjory Jolicoeur, MD, PhD, FRCPC—Chair\u003c\/p\u003e\n\u003cp\u003ePanel Question and Answer\u003c\/p\u003e\n\u003cp\u003ePoster Session A (Continued)\u003c\/p\u003e\n\u003cp\u003eWith Complimentary Wine and Cheese Reception\u003c\/p\u003e\n\u003cp\u003eTrials in Progress Poster Session A (Continued)\u003c\/p\u003e\n\u003cp\u003eWith Complimentary Wine and Cheese Reception\u003c\/p\u003e\n\u003cp\u003ePoster Walks: Prostate CancerMarjory Jolicoeur, MD, PhD, FRCPC\u003c\/p\u003e\n\u003cp\u003eHôpital Charles-LeMoyne\u003c\/p\u003e\n\u003cp\u003ePoster Walk LeaderChanning Judith Paller, MD\u003c\/p\u003e\n\u003cp\u003eThe Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins\u003c\/p\u003e\n\u003cp\u003ePoster Walk Leader\u003c\/p\u003e\n\u003cp\u003e6:00 PM-\u003c\/p\u003e\n\u003cp\u003e6:45 PM\u003c\/p\u003e\n\u003cp\u003eWomen’s Networking Reception\u003c\/p\u003e\n\u003cp\u003eFriday, February 14, 2025\u003c\/p\u003e\n\u003cp\u003eComplimentary Continental Breakfast\u003c\/p\u003e\n\u003cp\u003eExhibits Open\u003c\/p\u003e\n\u003cp\u003eOral Abstract Session B: Urothelial CarcinomaElizabeth A. Guancial, MD—Chair\u003c\/p\u003e\n\u003cp\u003eFlorida Cancer Specialists \u0026amp; Research InstituteNicholas I. Simon, MD, MSc—Chair\u003c\/p\u003e\n\u003cp\u003eNational Cancer InstituteAndrea B Apolo, MD\u003c\/p\u003e\n\u003cp\u003eWelcome of the Day\u003c\/p\u003e\n\u003cp\u003eElizabeth R. Plimack, MD, FASCO, MS\u003c\/p\u003e\n\u003cp\u003eFox Chase Cancer Center, Temple Health\u003c\/p\u003e\n\u003cp\u003eDiscussion\u003c\/p\u003e\n\u003cp\u003eScot Anthony Niglio, MD, MS\u003c\/p\u003e\n\u003cp\u003eNational Institutes of Health Division of Occupational Health and Safety\u003c\/p\u003e\n\u003cp\u003eDiscussion\u003c\/p\u003e\n\u003cp\u003ePanel Question and Answer\u003c\/p\u003e\n\u003cp\u003eBreak\u003c\/p\u003e\n\u003cp\u003eCase-Based Session: Non-Muscle Invasive Bladder Cancer: Exploring Therapies Beyond Bacillus Calmette-GuérinBrian Christopher Baumann, MD—Chair\u003c\/p\u003e\n\u003cp\u003eSpringfield ClinicBogdana Schmidt, MD, MPH—Chair\u003c\/p\u003e\n\u003cp\u003eUniversity of Utah\u003c\/p\u003e\n\u003cp\u003eThe Changing World of Non-Muscle Invasive Bladder CancerCase Presentation\u003c\/p\u003e\n\u003cp\u003eGirish S. Kulkarni, MD, PhD\u003c\/p\u003e\n\u003cp\u003eDepartment of Surgical Oncology, Princess Margaret Cancer Center, University Health Network\u003c\/p\u003e\n\u003cp\u003eUrology\u003c\/p\u003e\n\u003cp\u003eMark Tyson, MPH\u003c\/p\u003e\n\u003cp\u003eMayo Clinic Arizona\u003c\/p\u003e\n\u003cp\u003eUrology\u003c\/p\u003e\n\u003cp\u003eTracy L Rose, MD\u003c\/p\u003e\n\u003cp\u003eUniversity of North Carolina at Chapel Hill\u003c\/p\u003e\n\u003cp\u003eMedical Oncology\u003c\/p\u003e\n\u003cp\u003ePanel Question and Answer\u003c\/p\u003e\n\u003cp\u003ePoster Session B: Urothelial Carcinoma\u003c\/p\u003e\n\u003cp\u003eWith Complimentary Boxed Lunch\u003c\/p\u003e\n\u003cp\u003eTrials in Progress Poster Session B: Urothelial Carcinoma\u003c\/p\u003e\n\u003cp\u003eWith Complimentary Boxed Lunch\u003c\/p\u003e\n\u003cp\u003eBreakout Session: Emerging Trends and Advances in Germ Cell TumorsAditya Bagrodia, MD—Chair\u003c\/p\u003e\n\u003cp\u003eUniversity of California, San Diego HealthAnja Lorch, MD—Chair\u003c\/p\u003e\n\u003cp\u003eUniversitätsspital ZürichNabil Adra, MD\u003c\/p\u003e\n\u003cp\u003eIndiana University Health Melvin and Bren Simon Comprehensive Cancer Center\u003c\/p\u003e\n\u003cp\u003eHigh-Dose Chemotherapy in Testicular Cancer: Current Evidence and Clinical Indications\u003c\/p\u003e\n\u003cp\u003eAxel Heidenreich, MD\u003c\/p\u003e\n\u003cp\u003eUniversity Hospital of Cologne\u003c\/p\u003e\n\u003cp\u003ePrimary Retroperitoneal Lymph Node Dissection in Stage II Seminoma: Management Strategies and Current Controversies\u003c\/p\u003e\n\u003cp\u003eDarren R. Feldman, MD\u003c\/p\u003e\n\u003cp\u003eMemorial Sloan Kettering Cancer Center\u003c\/p\u003e\n\u003cp\u003eLandscape of New Trials and Targets in Refractory Germ Cell Tumors\u003c\/p\u003e\n\u003cp\u003ePanel Question and Answer\u003c\/p\u003e\n\u003cp\u003eThe ABCs of ADCs: Unleashing the Power of Antibody-Drug Conjugates in Advanced Bladder CancerKent William Mouw, MD, PhD—Chair\u003c\/p\u003e\n\u003cp\u003eDana-Farber Cancer Institute, Brigham and Women’s HospitalBenjamin Garmezy, MD—Chair\u003c\/p\u003e\n\u003cp\u003eSarah Cannon Research InstituteDi Maria Jiang, MD, MSc, FRCPC\u003c\/p\u003e\n\u003cp\u003ePrincess Margaret Hospital, University Health Network\u003c\/p\u003e\n\u003cp\u003eTargeting Bladder Cancer With Antibody Drug Conjugates\u003c\/p\u003e\n\u003cp\u003eFunda Meric-Bernstam, MD, FASCO\u003c\/p\u003e\n\u003cp\u003eUniversity of Texas MD Anderson Cancer Center\u003c\/p\u003e\n\u003cp\u003eHER2 Antibody-Drug Conjugate Therapy: A New Frontier in Bladder Cancer\u003c\/p\u003e\n\u003cp\u003eDaniel Castellano, MD\u003c\/p\u003e\n\u003cp\u003eServicio de Oncología Médica, Hospital Universitario 12 de Octubre\u003c\/p\u003e\n\u003cp\u003eOvercoming Challenges of Antibody-Drug Conjugate Toxicity in Bladder Cancer\u003c\/p\u003e\n\u003cp\u003eTerence W. Friedlander, MD\u003c\/p\u003e\n\u003cp\u003eUniversity of California, San Francisco Medical Center\u003c\/p\u003e\n\u003cp\u003eBetter Together? Exploring Novel Drug Combinations With Antibody-Drug Conjugates\u003c\/p\u003e\n\u003cp\u003ePanel Question and Answer\u003c\/p\u003e\n\u003cp\u003eBreak\u003c\/p\u003e\n\u003cp\u003ePanning for Gold: The Role of ctDNA as a Biomarker for Bladder CancerBernadett Szabados, MBBS—Chair\u003c\/p\u003e\n\u003cp\u003eBarts Cancer CentreJoaquim Bellmunt, MD—Chair\u003c\/p\u003e\n\u003cp\u003eDana-Farber Cancer InstituteRoger Li, MD\u003c\/p\u003e\n\u003cp\u003eH. Lee Moffitt Cancer Center and Research Institute\u003c\/p\u003e\n\u003cp\u003eCapturing What You Cannot See: How Can ctDNA Be Used to Improve Clinical Staging for Upper Tract Disease?\u003c\/p\u003e\n\u003cp\u003eAlexander William Wyatt, PhD\u003c\/p\u003e\n\u003cp\u003eVancouver Prostate Centre, University of British Columbia\u003c\/p\u003e\n\u003cp\u003eEvolution of Ctdna Detection with Next Generation Technology\u003c\/p\u003e\n\u003cp\u003eNimira S. Alimohamed, FRCPC\u003c\/p\u003e\n\u003cp\u003eArthur Child Comprehensive Cancer Centre, University of Calgary\u003c\/p\u003e\n\u003cp\u003ePotential Impact of ctDNA on Perioperative Management of Muscle-Invasive Bladder Cancer\u003c\/p\u003e\n\u003cp\u003eGillian Vandekerkhove, PhD, MSc\u003c\/p\u003e\n\u003cp\u003eVancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia\u003c\/p\u003e\n\u003cp\u003eBeneath the Surface: Unleashing the Potential of Ctdna across the Spectrum of Urothelial Carcinoma\u003c\/p\u003e\n\u003cp\u003ePanel Question and Answer\u003c\/p\u003e\n\u003cp\u003eRapid Oral Abstract Session B: Urothelial CarcinomaKatie S. Murray, DO, FACS, MS—Chair\u003c\/p\u003e\n\u003cp\u003eABSTRACT 666: Clinically advanced urothelial bladder cancer (CAUBC) in young onset bladder cancer (YOUC) patients: A genomic landscape study.\u003c\/p\u003e\n\u003cp\u003ePanel Question and Answer\u003c\/p\u003e\n\u003cp\u003ePoster Session B (Continued)\u003c\/p\u003e\n\u003cp\u003eWith Complimentary Wine and Cheese Reception\u003c\/p\u003e\n\u003cp\u003eTrials in Progress Poster Session B (Continued)\u003c\/p\u003e\n\u003cp\u003eWith Complimentary Wine and Cheese Reception\u003c\/p\u003e\n\u003cp\u003ePoster Walks: Urothelial CarcinomaElias Chandran, FRACP, MBBS\u003c\/p\u003e\n\u003cp\u003eNational Cancer Institute\u003c\/p\u003e\n\u003cp\u003ePoster Walk LeaderArmine Smith, MD\u003c\/p\u003e\n\u003cp\u003eJohns Hopkins University School of Medicine\u003c\/p\u003e\n\u003cp\u003ePoster Walk Leader\u003c\/p\u003e\n\u003cp\u003eSaturday, February 15, 2025\u003c\/p\u003e\n\u003cp\u003eComplimentary Continental Breakfast\u003c\/p\u003e\n\u003cp\u003ePoster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers\u003c\/p\u003e\n\u003cp\u003eTrials in Progress Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers\u003c\/p\u003e\n\u003cp\u003eOral Abstract Session C: Renal Cell CancerArpita Desai, MD—Chair\u003c\/p\u003e\n\u003cp\u003eUniversity of California, San FranciscoDaniel Shapiro—Chair\u003c\/p\u003e\n\u003cp\u003eUniversity of Wisconsin-MadisonTodd Matthew Morgan, MD\u003c\/p\u003e\n\u003cp\u003eWelcome of the Day\u003c\/p\u003e\n\u003cp\u003eTian Zhang, MD, MHS\u003c\/p\u003e\n\u003cp\u003eUT Southwestern University\u003c\/p\u003e\n\u003cp\u003eDiscussion\u003c\/p\u003e\n\u003cp\u003eABSTRACT 618: Prospective COTRIMS (Cologne trial of retroperitoneal lymphadectomy in metastatic seminoma) trial: Final results.\u003c\/p\u003e\n\u003cp\u003eClint Cary, MD, MBA, MPH\u003c\/p\u003e\n\u003cp\u003eIndiana University Simon Comprehensive Cancer Center\u003c\/p\u003e\n\u003cp\u003eDiscussion\u003c\/p\u003e\n\u003cp\u003ePanel Question and Answer\u003c\/p\u003e\n\u003cp\u003eBreak\u003c\/p\u003e\n\u003cp\u003eBiomarkers and Adjuvant Therapy for Renal Cell Carcinoma: Current State and Future DirectionsShuchi Gulati, MD, MS, FACP—Chair\u003c\/p\u003e\n\u003cp\u003eUniversity of California, Davis Comprehensive Cancer CenterAxel Bex, MD, PhD—Chair\u003c\/p\u003e\n\u003cp\u003eSimpa Samuel Salami, MD, MPH\u003c\/p\u003e\n\u003cp\u003eUniversity of Michigan\u003c\/p\u003e\n\u003cp\u003eBiomarkers in Renal Cell Carcinoma: Dead End or Turning Point?\u003c\/p\u003e\n\u003cp\u003eSamra Turajlic, MD, PhD\u003c\/p\u003e\n\u003cp\u003eThe Francis Crick Institute\u003c\/p\u003e\n\u003cp\u003eThe Future of Biomarkers in Renal Cell Carcinoma\u003c\/p\u003e\n\u003cp\u003eLaurence Albiges, MD, PhD\u003c\/p\u003e\n\u003cp\u003eGustave Roussy, Université Paris Saclay\u003c\/p\u003e\n\u003cp\u003eAdjuvant Therapy in Renal Cell Cancer: A Practical Guide\u003c\/p\u003e\n\u003cp\u003ePanel Question and Answer\u003c\/p\u003e\n\u003cp\u003ePoster Session C (Continued)\u003c\/p\u003e\n\u003cp\u003eWith Complimentary Boxed Lunch\u003c\/p\u003e\n\u003cp\u003eTrials in Progress Poster Session C (Continued)\u003c\/p\u003e\n\u003cp\u003eWith Complimentary Boxed Lunch\u003c\/p\u003e\n\u003cp\u003eWomen in Genitourinary Cancers Networking LuncheonView the networking faculty list here\u003c\/p\u003e\n\u003cp\u003ePoster Walks: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral CancersBrittney Cotta, MD\u003c\/p\u003e\n\u003cp\u003eUniversity of Texas MD Anderson Cancer Center\u003c\/p\u003e\n\u003cp\u003ePoster Walk LeaderShuchi Gulati, MD, FACP, MS\u003c\/p\u003e\n\u003cp\u003eUC Davis Comprehensive Cancer Center\u003c\/p\u003e\n\u003cp\u003ePoster Walk Leader\u003c\/p\u003e\n\u003cp\u003e12:45 PM-\u003c\/p\u003e\n\u003cp\u003e​​​​​​​1:30 PM\u003c\/p\u003e\n\u003cp\u003eRapid Oral Abstract Session C: Renal Cell CancerBrittney Cotta, MD—Chair\u003c\/p\u003e\n\u003cp\u003eABSTRACT 444: Final overall survival and new ctDNA analysis in MET-driven advanced papillary renal cancer (CALYPSO).\u003c\/p\u003e\n\u003cp\u003eABSTRACT 1: EPIC-A: Phase II trial of cemiplimab plus standard of care chemotherapy followed by maintenance cemiplimab in locally advanced or metastatic penile carcinoma.\u003c\/p\u003e\n\u003cp\u003ePanel Question and Answer\u003c\/p\u003e\n\u003cp\u003eCase-Based Session: Failure of Immunotherapy in Renal Cell Cancer: What’s Next?Leslie K. Ballas, MD—Chair\u003c\/p\u003e\n\u003cp\u003eCedars-Sinai Medical CenterKathryn Hacker Gessner, MD, PhD—Chair\u003c\/p\u003e\n\u003cp\u003eUNC School of MedicineMaria T. Bourlon, MD, MSc, FASCO\u003c\/p\u003e\n\u003cp\u003eInstituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán\u003c\/p\u003e\n\u003cp\u003eMedical Oncology\u003c\/p\u003e\n\u003cp\u003eMatthew T Campbell, MD, MS\u003c\/p\u003e\n\u003cp\u003eThe University of Texas MD Anderson Cancer Center\u003c\/p\u003e\n\u003cp\u003eMedical Oncology\u003c\/p\u003e\n\u003cp\u003eRaquibul Hannan, MD, PhD\u003c\/p\u003e\n\u003cp\u003eUniversity of Texas Southwestern Medical Center\u003c\/p\u003e\n\u003cp\u003eRadiation Oncology\u003c\/p\u003e\n\u003cp\u003eViraj A. Master, MD, PhD\u003c\/p\u003e\n\u003cp\u003eEmory School of Medicine\u003c\/p\u003e\n\u003cp\u003eUrology\u003c\/p\u003e\n\u003cp\u003ePanel Question and Answer\u003c\/p\u003e","brand":"Medicalcoursespro","offers":[{"title":"Default Title","offer_id":46405726437572,"sku":null,"price":208.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0751\/7644\/4100\/files\/American-Society-of-Clinical-Oncology-Genitourinary-Cancers-Symposium-2025.jpg?v=1784215410","url":"https:\/\/medicalcoursespro.com\/products\/american-society-of-clinical-oncology-genitourinary-cancers-symposium-2025","provider":"Medicalcoursespro","version":"1.0","type":"link"}